Alfred Ian Lee, MD, PhD

Assistant Professor of Medicine (Hematology); Firm Chief, Inpatient Hematology, Yale Cancer Center; Assistant Program Director, Traditional Internal Medicine Residency Program

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Hematology Program

Internal Medicine: Hematology

Yale Medical Group

Board Certifications

  • Internal Medicine AB of Internal Medicine (2007)

  • Hematology (Internal Medicine) AB of Internal Medicine (2013)

Clinical Trials

Conditions Study Title
Unknown Sites Study of Immune System in Patients with Cancer and Blood Disorders
Hodgkin's Lymphoma, Leukemia, not otherwise specified, Multiple Myeloma, Non-Hodgkin's Lymphoma Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study
An ascending single dose study to evaluate the safety, tolerability and pharmacokinetics/pharmacodynamics of PF-05280602, a recombinant factor VIIa variant (813D), in adult hemophilia A and B subjects with or without inhibitors.
Comparison of Gut Commensal Bacteria Between Persistently anti-gamma2 Glycoprotein-I Positive Patients and Antiphospholipid Antibody Negative Patients
Unknown Sites Specimen Repository for Hematologic Diseases
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease
Myeloid and Monocytic Leukemia A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Myeloid and Monocytic Leukemia A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory AML Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)
Myeloid and Monocytic Leukemia A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Edit this profile

Contact Info

Alfred Ian Lee, MD, PhD
Patient Care Location
Yale HematologySmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 7

New Haven, CT 06511
Mailing Address
PO Box 208021
New Haven, CT 06520-8021